Oxidoreductases (1. ) (e.g., Catalase, Dehydrogenases, Reductases, Etc.) Patents (Class 424/94.4)
  • Patent number: 10408823
    Abstract: The present invention is directed to methods for improving assay specificity and performance in binding assays.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 10, 2019
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Anahit Aghvanyan, Eli N. Glezer, John Kenten, George Sigal, Martin Stengelin, David Routenberg
  • Patent number: 10383921
    Abstract: Disclosed herein are compositions and methods for providing an antioxidant effect to a subject, e.g., modulating or otherwise improving oxidative stress pathways and/or neutralizing or reducing damaging reactive oxygen species (ROS).
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: August 20, 2019
    Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, COMPAGNIE GERVAIS DANONE
    Inventors: Wendy S. Garrett, Patrick Veiga, Sonia Arora Ballal, Johan van Hylckama Vlieg, Gaëlle Quéré, Peggy Garault
  • Patent number: 10266493
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 23, 2019
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Patent number: 10251408
    Abstract: The present invention provides a composition comprising a tea extract or a catechin and a citrus fruit extract or a flavanone or a glycoside thereof.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: April 9, 2019
    Assignee: Kyushu University, National University Corporation
    Inventor: Hirofumi Tachibana
  • Patent number: 10196625
    Abstract: Provided herein is a means for increasing protein retention in blood. The protein retention in blood is increased by forming a conjugate of a protein and chondroitin produced by a microorganism having chondroitin-producing capability and/or chondroitin synthesized with a chondroitin synthase.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 5, 2019
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Yoshihiro Takatsu, Masanobu Fukushima
  • Patent number: 10189008
    Abstract: The present invention relates to a water-absorbing composition comprising at least i) 89 to 99.89 wt % of at least one water-absorbing polymer; ii) 0.1 to 10 wt % of at least one oxidizing agent; iii) 0.01 to 1 wt % of at least one inhibitor to inhibit free-radical polymerizations; wherein the weight quantities are each based on the overall weight of the water-absorbing composition. The present invention also relates to a process for producing a water-absorbing composition, the water-absorbing composition obtainable by this process, a composite, a process for producing a composite, the composite obtainable by this process, chemical products such as foams, moldings, fibers, foils, films, cables, sealing materials, liquid-imbibing hygiene articles, carriers for plant and fungal growth regulators, packaging materials, soil additives or building products and also the use of a water-absorbing composition.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: January 29, 2019
    Assignee: Evonik Degussa GmbH
    Inventors: Laurent Wattebled, Jessica Pillat, Lisa Maus, Scott Smith, Jorg Harren
  • Patent number: 10183026
    Abstract: A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against ?-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: January 22, 2019
    Assignee: THE SECRETARY, DEPARTMENT OF ATOMIC ENERGY
    Inventors: Deepak Sharma, Santosh Kumar Sandur, Rahul Checker, Raghavendra Shridhar Patwardhan, Vikram Prakash Gota, Jayakumar Sundarraj, Preetha Sasi, Subrata Chattopadhyay
  • Patent number: 10123965
    Abstract: The present disclosure provides formulations, methods and devices for periorbital skin rejuvenation. A periorbital skin serum in accordance with the present disclosure comprises squalane (sugarcane derived), vitamin E (tocopheryl acetate), vitamin C (tetrahexyldecyl ascorbate), and ubiquinone (coenzyme Q10, oxidized form).
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: November 13, 2018
    Assignee: YOUNIQUE, LLC
    Inventor: Mukhtar Siddiqui
  • Patent number: 10125176
    Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 13, 2018
    Assignee: OXTHERA INTELLECTUAL PROPERTY AB
    Inventors: Elisabeth Lindner, Helena Cowley, Aaron Cowley, Maria Akerman
  • Patent number: 10066025
    Abstract: The invention described herein relates to the discovery that renalase, and fragments thereof, are useful for the treatment or prevention of cardiac and renal diseases or disorders. Thus, the invention relates to compositions comprising renalase, or fragments thereof, and methods for treating and preventing cardiac and renal disease or disorders.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 4, 2018
    Assignee: YALE UNIVERSITY
    Inventor: Gary Desir
  • Patent number: 10016481
    Abstract: An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: July 10, 2018
    Assignee: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Ken Katoh, Hiroshi Ueno, Yuko Ono, Noriko Ueda, Toshiya Kobayashi, Takahiro Moriya, Yutaro Obara
  • Patent number: 9949913
    Abstract: The present invention features novel cosmetic skin care compositions for improving the appearance of skin, particularly the reducing the appearance of age spots and discoloration.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: April 24, 2018
    Assignee: Jan Marini Skin Research
    Inventors: Jan Marini, Subhash J. Saxena
  • Patent number: 9938176
    Abstract: The present invention provides efficient, economical, and environmentally-friendly compositions and methods for removing pollutants from water sources. In particular embodiments, the present invention provides compositions and methods for catalyzing the degradation of pharmaceutical pollutants in wastewater using the enzyme chloroperoxidase (CPO). Another embodiment provides a method of degrading pollutants in wastewater and other water sources. In specific embodiments, the claimed composition and method can be used to degrade pharmaceutical pollutants selected from the group consisting of: acetaminophen, carbamazepine, sulfamethazine, diclofenac, and naproxen.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 10, 2018
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Xiaotang Wang, Qinghao He
  • Patent number: 9896532
    Abstract: The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, cashew nut, and Asian lacquer.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: February 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Rebecca Braslau
  • Patent number: 9885024
    Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: February 6, 2018
    Assignees: DUKE UNIVERSITY, HORIZON PHARMA RHEUMATOLOGY LLC
    Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
  • Patent number: 9801902
    Abstract: The present invention relates to methods for removal of dead tissue from wounds or skin using topical nitric oxide donor devices and/or compositions. In one embodiment, the present invention relates to a transdermal patch device that is designed to deliver nitric oxide. In another embodiment, the present invention relates to one or more devices and/or compositions that are designed to deliver nitric oxide and optionally one or more other compounds, where such devices/compositions include, without limitation, bandages, layered bandages, adhesive bandages, transdermal patches, creams, ointments, or a any combination of two or more thereof.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: October 31, 2017
    Assignees: The University of Akron, KCI USA, Inc.
    Inventors: Daniel J. Smith, Patrick John Trotter, Mahesh Bhide
  • Patent number: 9782459
    Abstract: Eosinophil peroxidase compositions and methods of their use for killing and/or inhibiting the growth of susceptible microorganisms are provided. The compositions include an eosinophil peroxidase, a peroxide or peroxide source, and amino acids glycine, L-alanine, and L-proline.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 10, 2017
    Assignee: EXOXEMIS, INC.
    Inventors: Jackson T. Stephens, Jr., Matthew J. Pete
  • Patent number: 9750272
    Abstract: This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of cardiovascular disease or type 2 diabetes, and also in the prevention and/or management of obesity and generally in weight management and loss. Thus a meal intended for human consumption is provided, the meal comprising: (a) 250-650 kilocalories (1045-4180 kiloJoules); (b) 10-50, preferably 20-50, more preferably 30-50 g fiber; (c) 10-50, preferably 10-30, more preferably 10-20 g protein; (d) 0 to 5, preferably less than 3 g starch; and (e) 0 to 2, preferably 0 to 1, most preferably 0 to 0.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 5, 2017
    Assignee: Conopco, Inc.
    Inventors: Mark John Berry, Heather Frances Jennifer Bligh, Mark Ian Fowler, Karl John Hunter, Katrina Macaulay
  • Patent number: 9730888
    Abstract: The invention provides methods for enhancing the delivery of therapeutic compounds to the eye of a subject by administering plasmin or derivatives thereof and the therapeutic compounds to the eye.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 15, 2017
    Assignee: Wayne State University
    Inventors: Zhuo-Hua Pan, Elena Ivanova
  • Patent number: 9492592
    Abstract: A method of treating a tear in a knee meniscus of a patient. The method includes exposing the torn knee meniscus to a protein crosslinker during surgery to repair the tear. Also provided is a fixation device for the surgical repair of tears of the meniscus of the knee, where the device contains one or more protein crosslinking reagents.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 15, 2016
    Assignee: Orthopeutics, L. P.
    Inventors: Thomas P. Hedman, Pawel Slusarewicz
  • Patent number: 9468670
    Abstract: Methods and composition for a melatonin signaling modulator-based diagnosis and therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a melatonin signaling modulator are described. Furthermore, the invention provides compositions and methods for detecting biliary tract disease such as cholangiocarcinoma.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 18, 2016
    Assignees: Texas A&M University System, The United States of America as Represented by the Department of Veterans Affairs, Scott & White Healthcare
    Inventors: Gianfranco Alpini, Sharon DeMorrow, Shannon Glaser
  • Patent number: 9415046
    Abstract: The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: August 16, 2016
    Assignee: YALE UNIVERSITY
    Inventors: Wajahat Z. Mehal, Themis Kyriakides
  • Patent number: 9377454
    Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: June 28, 2016
    Assignee: CREALTA PHARMACEUTICALS LLC
    Inventors: Theresa Rosario-Jansen, David Erick Wright
  • Patent number: 9283202
    Abstract: Methods have been developed for incorporation of peracid compounds and related compositions into a non-aqueous medium. The peracid incorporated into the non-aqueous medium is stable and keeps its chemical and antimicrobial activity for extended durations. The non-aqueous medium may be removed just prior to or during application of the peracid.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 15, 2016
    Assignee: CHD Bioscience, Inc.
    Inventors: Edwin D. Neas, Michael K. Handley, Kevin S. Marchitto, Stephen T. Flock, Charles Henry
  • Patent number: 9260495
    Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 16, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
  • Patent number: 9259005
    Abstract: The present invention is directed to methods for inhibiting growth of pathogens and to substrates with selenium nanoparticles or selenium nanoclusters having antipathogenic properties.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: February 16, 2016
    Assignee: Brown University
    Inventors: Thomas J. Webster, Phong Anh Tran
  • Patent number: 9249432
    Abstract: Disclosed herein are enzymes and combinations of the enzymes useful for the hydrolysis of cellulose and the conversion of biomass. Methods of degrading cellulose and biomass using enzymes and cocktails of enzymes are also disclosed.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 2, 2016
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Roman Brunecky, Michael E. Himmel
  • Patent number: 9181542
    Abstract: The present invention relates to a method for increasing chaperone activity by irradiating peroxiredoxin (Prx) proteins. More particularly, the present invention may be useful for preparing recombinant proteins imparting resistance against various environmental stresses by increasing the chaperone activity of peroxiredoxin, since it has been observed that irradiated peroxiredoxin has enhanced chaperone activity characteristics, wherein an ?-helix structure decreases while a ?-sheet structure increases, from analysis results of a protein structure change and chaperone activity after irradiating two types of peroxiredoxins (2-Cys, 3-Cys) which are two active cysteine motifs of peroxiredoxin.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: November 10, 2015
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Byung Yeoup Chung, Seung Sik Lee, Byung Chull An, Eun Mi Lee, Jae Taek Lee, Hyoung-Woo Bai
  • Patent number: 9107901
    Abstract: Provided are compositions that include one or more natural, recombinant and/or modified allergens; with a pharmaceutically acceptable non-aqueous solvent to form an immunotherapy composition that includes the active ingredient and solvent, wherein the immunotherapy composition is formulated for administration to a subject in need of immunotherapy. The solvent is miscible with water and interstitial fluid. The at least one active ingredient is soluble in the solvent and insoluble in water and in an aqueous phase of interstitial fluid. The present compositions may be administered to a patient for example, as part of an immunotherapy regimen to help induce a state of immunologic tolerance to one or more allergies, or as treatment for an autoimmune disease. Also provided are methods of making such compositions. Further provided are methods that include administering the composition to a mammal.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: August 18, 2015
    Inventor: Robert E. Coifman
  • Patent number: 9109218
    Abstract: The present invention provides a site-directed mutated arginase and the preparation method thereof, and the use of said site-directed mutated arginase in preparing a medicament for treating an arginase-related disease. The present invention also provides a pegylated arginase and the preparation method thereof, and the use of said pegylated arginase in preparing a medicament for treating an arginase-related disease.
    Type: Grant
    Filed: December 23, 2012
    Date of Patent: August 18, 2015
    Assignee: Bio-Cancer Treatment International Ltd. (Shanghai)
    Inventors: Ning Man Cheng, Li Chen
  • Patent number: 9040579
    Abstract: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: May 26, 2015
    Assignee: Chemigen
    Inventor: Yansheng Du
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Publication number: 20150132276
    Abstract: It is an object of the present invention to provide a chondrogenesis promoter that is safe and exhibits a chondrogenesis-promoting effect by daily ingestion. It is also an object of the invention to provide a proteoglycan synthesis promoter that exhibits a proteoglycan synthesis-promoting effect by ingestion. Provided are a chondrogenesis promoter and a proteoglycan synthesis promoter each containing a milk-derived basic protein fraction as an active ingredient. Synthesis of proteoglycan and formation of a cartilage can be promoted by oral ingestion of the milk-derived basic protein fraction. A hydrolysate of the milk-derived basic protein fraction also has a similar chondrogenesis-promoting effect.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Yoshihiko Takano, Takayuki Nara, Ken Kato, Yoshikazu Morita
  • Publication number: 20150132275
    Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 14, 2015
    Applicant: BIOHIT OYJ
    Inventor: Osmo Suovaniemi
  • Publication number: 20150118214
    Abstract: Provided are a pharmaceutical composition containing human cyclooxygenase and doxorubicin or a doxorubicin analogue using Salvia plectranthoides (also referred to as rare grass) as a crude drug, a preparation method therefor and the use thereof in preparing drugs for treating nephritis, cholecystitis and gallbladder polyps, tumours or antiphlogistic and analgesic drugs.
    Type: Application
    Filed: December 13, 2012
    Publication date: April 30, 2015
    Inventor: Xiuying LIN
  • Patent number: 9005608
    Abstract: Methods and compositions are described whereby poorly water-soluble beneficial agents such as vitamins and co-factors are formulated into self-emulsifying formulas (SEF) and optionally sorbing the SEF into pores of porous solid particulates, or preparing supersaturated solutions (SSS) and sorbing the SSS into pores of porous solid particulates. These formulations are useful as dosage forms with oral availability.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: April 14, 2015
    Assignee: Adds Pharmaceuticals LLC
    Inventors: Liang C. Dong, Katrina Andrea U. Co, Shu Li, Crystal Pollock-Dove
  • Publication number: 20150098932
    Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventor: Sarah Bacus
  • Patent number: 8999686
    Abstract: Methods and compositions, including nucleotide sequences, amino acid sequences, and host cells, for producing fatty alcohols are described.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: April 7, 2015
    Assignee: REG Life Sciences, LLC
    Inventors: Zhihao Hu, Vikranth Arlagadda
  • Publication number: 20150093430
    Abstract: The present invention refers to diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: April 18, 2013
    Publication date: April 2, 2015
    Applicant: DR HEALTHCARE ESPAÑA, S.L.
    Inventors: Carlos Duelo Riu, Juan José Duelo Riu
  • Publication number: 20150079111
    Abstract: Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided.
    Type: Application
    Filed: June 5, 2013
    Publication date: March 19, 2015
    Inventor: Jonas AXELSSON
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150071903
    Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
    Type: Application
    Filed: August 18, 2014
    Publication date: March 12, 2015
    Applicant: President and Fellows of Harvard College
    Inventors: David R. Liu, John Anthony Zuris, David B. Thompson
  • Publication number: 20150071904
    Abstract: Provided herein are compositions and methods comprising ROS target modulators that increase ROS flux and endogenus ROS production, thereby potentiating oxidative attack by antibiotics and biocides.
    Type: Application
    Filed: January 4, 2013
    Publication date: March 12, 2015
    Inventors: James J. Collins, Mark P. Brynildsen, Jonathan A. Winkler, Catherine Spina
  • Publication number: 20150064158
    Abstract: A purpose of the present invention is to provide a sense-improving agent which is safe and, when routinely taken or applied to the skin, exerts an effect of improving deterioration in peripheral sensation. Another purpose of the present invention is to provide a food, a drink, a feed or a cosmetic for improving sensation which exerts an effect of improving deterioration in peripheral sensation when orally taken or applied to the skin. The sense-improving agent comprises, as the active ingredient, a basic protein fraction derived from milk or a degraded basic protein fraction derived from milk. By orally taking the basic protein fraction derived from milk or the degraded basic protein fraction derived from milk or applying the same directly to the skin, deterioration in sensation, in particular, peripheral sensation can be improved. Thus, a food, a drink, a feed or a cosmetic for improving sensation can be obtained.
    Type: Application
    Filed: January 13, 2012
    Publication date: March 5, 2015
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Ken Katoh, Noriku Ueda, Hiroshi Ueno, Yuko Ono, Hiroko Nakahata, Takahiro Moriya, Daisaku Kobayashi
  • Publication number: 20150044190
    Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
    Type: Application
    Filed: April 16, 2014
    Publication date: February 12, 2015
    Applicant: National Jewish Health
    Inventor: Carl W. White
  • Patent number: 8946303
    Abstract: To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe so that long-term administration is possible. A composition containing reduced coenzyme Q was found to be effective for preventing and reducing fatigue, including muscle fatigue. Since the fatigue reducing effect of the composition of the present invention is seen not only in young rats but also more pronounced in aged rats, the present invention can provide the fatigue reducing agent which is very useful, especially, for middle-aged and older persons as well as for young people.
    Type: Grant
    Filed: January 19, 2004
    Date of Patent: February 3, 2015
    Assignee: Kaneka Corporation
    Inventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
  • Patent number: 8946256
    Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: February 3, 2015
    Assignee: Biocosmeceuticals, LLC
    Inventor: Sarah Bacus
  • Patent number: 8945540
    Abstract: Methods and compositions are provided for inhibiting the growth of susceptible microorganisms by contacting the microorganisms, in the presence of a peroxide and chloride or bromide, with myeloperoxidase and at least two activity enhancing agent amino acids.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: February 3, 2015
    Assignee: Exoxemis, Inc.
    Inventors: Sophie Becquerelle, William Haag, Obsidiana Abril-Horpel, Shri Valvani
  • Publication number: 20150030641
    Abstract: Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel.
    Type: Application
    Filed: February 19, 2013
    Publication date: January 29, 2015
    Inventors: Daniel G. Anderson, Zhen Gu, Robert S. Langer
  • Patent number: 8940295
    Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 27, 2015
    Assignee: Oxthera Intellectual Property AB
    Inventors: Harmeet Sidhu, Aaron Blake Cowley, Carl-Gustaf Golander, Qingshan Li